Skip to main content
. 2019 Aug 28;62(10):656–672. doi: 10.1002/jlcr.3750

Table 4.

Overview of clinical positron emission tomography (PET) tracers and study outcomes

Author + Year Compound Patients Peptide Dose Activity Dose Results Adverse Events
Gallium‐68
 Eriksson et al. 2014 [68Ga]Ga‐DO3A‐VS‐Cys40‐Exendin‐4 1 0.17 μg/kg 0.88 MBq/kg Detection of liver and lymph node metastases
 Antwi et al. 2015 [Nle14, Lys40(Ahx‐DOTA‐[68Ga]Ga)NH2]exendin‐4] 5 12.0‐15.3 μg 79.8 ± 3.9 MBq (76‐97 MBq) In four out of 5 patients that had surgery, an insulinoma was found in four of four patients ‐ Prophylactic glucose infusion was given before the injection
‐ Nausea (n = 1)
 Luo et al. 2015 [68Ga]Ga‐NOTA‐exendin‐4 1 Detection of insulinoma in the pancreas tail (SUVmax of 20.7)
 Cuthbertson et al. 2015 [68Ga]Ga‐NOTA‐exendin‐4 1 Detection of insulinoma
 Luo et al. 2016 [68Ga]Ga‐NOTA‐exendin‐4 1 51.8 MBq Detection of insulinoma in the pancreas tail (SUVmean of 20.0 and SUVmax of 52.9)
 Luo et al. 2016 [68Ga]Ga‐NOTA‐MAL‐Cys40‐exendin‐4 52 7‐25 μg 18.5‐185 MBq In 43 of 52 patients, surgery was performed. In 42 patients, an insulinoma was found (sensitivity of 97.7%) ‐ No hypoglycemia was observed because of continuous infusion of glucose
‐ Nausea (n = 2)
‐ Vomiting (n = 2)
 Luo et al. 2017 [68Ga]Ga‐exendin‐4 1 Detection of a lesion that was ablated with ethanol ablation (SUVmean of 5.7 and SUVmax of 10.8)
 Bongetti et al. 2018 [68Ga]Ga‐DOTA‐exendin‐4 1 The 68Ga‐DOTA‐exendin‐4 was suggestive of nesidioblastosis; however, an insulinoma as identified with SACST and EUS was missed, noting that the insulinoma was negative for GLP‐1R
 Parihar et al. 2018 [68Ga]Ga‐DOTA‐exendin‐4 1 Detection of insulinoma (SUVmax of 21)
 Antwi et al. 2018 [68Ga]Ga‐DOTA‐exendin‐4 52 11.6‐23.8 μg 82.4 ± 14.9 MBq (43‐106 MBq) Sensitivity 94.6% (88.6‐98.0) ‐ No hypoglycemia due to continuous infusion of glucose
‐ Nausea (n = 14) and vomiting (n = 1)